The earnings crater. AdvanSix Inc posted Q4 2025 EPS of $0.08, falling 80.0% short of the $0.40 consensus estimate—a dramatic miss that marks the chemical manufacturer’s steepest earnings shortfall since Q3 2023’s negative surprise. Revenue landed at $1.49B for the full fiscal year, down 6% year-over-year, as subdued phenol demand and balanced acetone markets continued to pressure the company’s core business. Shares slipped 1.6% to $17.81 in after-hours trading.
Margin compression deepens. The quarter’s collapse reflects mounting pressure across AdvanSix’s chemicals portfolio. Operating margin turned negative at -0.55% versus prior periods, while profit margin compressed to just 3.5%—down sharply from the company’s trailing twelve-month performance. Net income for Q3 (the most recent quarterly filing) showed a $2.6M loss, a stark reversal from the $31.4M profit generated in Q2. The company’s PE ratio of 9.3x suggests the market had already priced in weakness, but this miss exceeded even diminished expectations.
Industry headwinds persist. CEO Erin Kane acknowledged on the Q3 earnings call that the company has been “navigating challenging industry dynamics” with a focus on operational optimization. Management had telegraphed expectations for demand to “moderate back to cycle averages” after the highs of 2024, but the magnitude of the Q4 miss suggests conditions deteriorated faster than anticipated. Interim CFO Christopher Gramm noted Q3 sales of $374M declined approximately 6% versus the prior year—a trend that clearly accelerated into year-end.
SUSTAIN program timing shifts. Adding to near-term uncertainty, management disclosed on the Q3 call that government shutdown disruptions would push expected tax credit receipts from the SUSTAIN program into 2026. “The timing of when we would expect to receive the credits that we have applied for looks like that’s going to be shifting to 2026,” management stated—removing a potential cash flow catalyst from the immediate outlook. The company now trades at $17.82, roughly 15% below its 200-day average of $19.88 and well off the 52-week high near $21.
Valuation offers limited cushion. At 9.3x trailing earnings and 8.8x forward estimates, AdvanSix trades at a discount to historical norms, but the 80% earnings miss raises questions about the reliability of forward projections. Analysts maintain a $21 price target, implying 18% upside, yet the company’s negative operating margin and compressed profitability suggest further downward estimate revisions may be warranted before a bottom forms. Revenue growth has turned negative at -6%, and the chemicals sector broadly faces demand uncertainty tied to industrial production cycles.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post ASIX Stock Alert: AdvanSix Reports $0.08 EPS, Missing Estimates by 80% on Weak Chemical Demand first appeared on AlphaStreet News.
